AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33708965 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 375
Study 33709202 — intervention group
Group type: EXPERIMENTAL
Intervention: FACIT-Fatigue total score, symptom subscale, and impact subscale
Number of subjects: 40
Study 33709202 — intervention group
Group type: EXPERIMENTAL
Intervention: FACIT-Fatigue
Number of subjects: 40
Study 33709202 — intervention group
Group type: EXPERIMENTAL
Intervention: FACIT-Fatigue score thresholds
Number of subjects: 40
Study 33709288 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) replacement therapy
Number of subjects: 40
Study 33709325 — intervention group
Group type: EXPERIMENTAL
Intervention: 600-µm corneal pre-cut
Number of subjects: 24
Study 33709325 — intervention group
Group type: COMPARATOR
Intervention: Single-plane stab-incision
Number of subjects: 24
Study 33709325 — intervention group
Group type: COMPARATOR
Intervention: Stab incision group
Number of subjects: 24
Study 33709325 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-cut group
Number of subjects: 24
Study 33709329 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG-PET/CT
Number of subjects: 0
Study 33709779 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivosidenib
Number of subjects: 0
Study 33709779 — intervention group
Group type: COMPARATOR
Intervention: Control not specified
Number of subjects: 0
Study 33709930 — intervention group
Group type: EXPERIMENTAL
Intervention: NASCITA cohort study with web-based system for data collection and monitoring
Number of subjects: 5166
Study 33709945 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-assessment web-based triage app for COVID-19 symptoms
Number of subjects: 13000000
Study 33710029 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinetic glomerular filtration rate formulas (including Jelliffe, Chen, Chiou and Hsu, Moran and Myers, Yashiro, Seelhammer, and Brater)
Number of subjects: 57
Study 33710029 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary creatinine clearance
Number of subjects: 57
Study 33710029 — intervention group
Group type: EXPERIMENTAL
Intervention: Yashiro equation
Number of subjects: 57
Study 33710399 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole (first trimester exposure)
Number of subjects: 848
Study 33710399 — intervention group
Group type: COMPARATOR
Intervention: Control group (no atypical antipsychotic during pregnancy)
Number of subjects: 848
Study 33710523 — intervention group
Group type: EXPERIMENTAL
Intervention: First/second-generation EGFR-tyrosine kinase inhibitors (1G/2G EGFR-TKIs)
Number of subjects: 141
Study 33710523 — intervention group
Group type: COMPARATOR
Intervention: Other systemic treatments
Number of subjects: 141
Study 33710523 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsequent systemic treatment after progression on 1G/2G EGFR-TKIs
Number of subjects: 141
Study 33710523 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib after progression on 1G/2G EGFR-TKIs
Number of subjects: 141
Study 33710523 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing for T790M mutation
Number of subjects: 141
Study 33710614 — intervention group
Group type: COMPARATOR
Intervention: dupilumab
Number of subjects: 1262
Study 33710614 — intervention group
Group type: COMPARATOR
Intervention: mepolizumab
Number of subjects: 1262
Study 33710614 — intervention group
Group type: COMPARATOR
Intervention: omalizumab
Number of subjects: 1262
Study 33710626 — intervention group
Group type: COMPARATOR
Intervention: Enteral zinc supplementation
Number of subjects: 482
Study 33710976 — intervention group
Group type: EXPERIMENTAL
Intervention: Tedizolid phosphate (3-6 mg/kg, single oral or intravenous dose)
Number of subjects: 32
Study 33711074 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-003 (tetravalent live attenuated dengue vaccine)
Number of subjects: 0
Study 33711699 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte-Colony Stimulating Factors (G-CSF)
Number of subjects: 2920
Study 33711699 — intervention group
Group type: COMPARATOR
Intervention: No G-CSF
Number of subjects: 2920
Study 33712086 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichloroacetate (DCA) 6.25 mg/kg oral capsules twice daily for 6 weeks, potentially increasing to 12.5 mg/kg twice daily for another 6 weeks if pain is not adequately controlled
Number of subjects: 30
Study 33712090 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention Control Training (ACT) intervention, average 84 minutes of training over three visits.
Number of subjects: 12
Study 33712090 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye-tracking data quality was moderate.
Number of subjects: 12
Study 33712275 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node (SLN) ultrastaging
Number of subjects: 30
Study 33712377 — intervention group
Group type: EXPERIMENTAL
Intervention: ZNF804A genotype
Number of subjects: 72
Study 33712437 — intervention group
Group type: EXPERIMENTAL
Intervention: MD ARC-520
Number of subjects: 8
Study 33712505 — intervention group
Group type: EXPERIMENTAL
Intervention: RMW present (MIP <30 cmH2O)
Number of subjects: 366
Study 33712505 — intervention group
Group type: EXPERIMENTAL
Intervention: RMW present
Number of subjects: 366
Study 33712505 — intervention group
Group type: COMPARATOR
Intervention: RMW absent
Number of subjects: 366
Study 33712561 — intervention group
Group type: EXPERIMENTAL
Intervention: Exoskeletal-assisted walking (EAW) training using a powered exoskeleton (ReWalk)
Number of subjects: 8
Study 33712849 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax 400 mg/day (3-day ramp up in cycle 1) plus azacitidine 75 mg/m2 on days 1-7 per 28-day cycle
Number of subjects: 6
Study 33712849 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax plus azacitidine
Number of subjects: 6
Study 33713190 — intervention group
Group type: EXPERIMENTAL
Intervention: PET-positive nodules
Number of subjects: 32
Study 33713190 — intervention group
Group type: COMPARATOR
Intervention: PET-negative nodules
Number of subjects: 32
Study 33713190 — intervention group
Group type: EXPERIMENTAL
Intervention: PET-positive nodules with benign nodule
Number of subjects: 32
Study 33713190 — intervention group
Group type: COMPARATOR
Intervention: PET-negative nodule
Number of subjects: 32
Study 33713190 — intervention group
Group type: COMPARATOR
Intervention: Thyroid nodules without suspicious ultrasonographic findings
Number of subjects: 32
Study 33713216 — intervention group
Group type: EXPERIMENTAL
Intervention: HLX07 at 50 mg
Number of subjects: 19
Study 33713216 — intervention group
Group type: EXPERIMENTAL
Intervention: HLX07 at 100 mg
Number of subjects: 19
Study 33713216 — intervention group
Group type: EXPERIMENTAL
Intervention: HLX07 at 200 mg
Number of subjects: 19
Study 33713216 — intervention group
Group type: EXPERIMENTAL
Intervention: HLX07 at 400 mg
Number of subjects: 19
Study 33713216 — intervention group
Group type: EXPERIMENTAL
Intervention: HLX07 at 600 mg
Number of subjects: 19
Study 33713216 — intervention group
Group type: EXPERIMENTAL
Intervention: HLX07 at 800 mg
Number of subjects: 19
Study 33713409 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline treatment
Number of subjects: 189
Study 33713409 — intervention group
Group type: COMPARATOR
Intervention: Nicotine patch
Number of subjects: 189
Study 33713409 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 189
Study 33713731 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Number of subjects: 1803
Study 33713742 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin at 30 mg/m² with adjuvant radiation therapy
Number of subjects: 55
Study 33713742 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin at 10 mg/m²
Number of subjects: 55
Study 33713742 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin at 40 mg/m²
Number of subjects: 55
Study 33714009 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib alone
Number of subjects: 70
Study 33714009 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib plus cisplatin
Number of subjects: 70
Study 33714009 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib plus durvalumab
Number of subjects: 70
Study 33714009 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin-containing chemoradiation
Number of subjects: 70
Study 33714009 — intervention group
Group type: COMPARATOR
Intervention: Nivolumab
Number of subjects: 70
Study 33714271 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional capacity of >4 MET
Number of subjects: 296
Study 33714271 — intervention group
Group type: COMPARATOR
Intervention: Functional capacity of <4 MET
Number of subjects: 296
Study 33714271 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrarenal cohort (>4 MET)
Number of subjects: 296
Study 33714271 — intervention group
Group type: COMPARATOR
Intervention: Infrarenal cohort (<4 MET)
Number of subjects: 296
Study 33714271 — intervention group
Group type: COMPARATOR
Intervention: Open surgical technique (<4 MET)
Number of subjects: 296
Study 33714271 — intervention group
Group type: EXPERIMENTAL
Intervention: >4 MET
Number of subjects: 296
Study 33714271 — intervention group
Group type: COMPARATOR
Intervention: <4 MET
Number of subjects: 296
Study 33714271 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 296
Study 33714278 — intervention group
Group type: EXPERIMENTAL
Intervention: CAD screening procedure during the selection period (2008-2015)
Number of subjects: 90000
Study 33714278 — intervention group
Group type: COMPARATOR
Intervention: No CAD screening
Number of subjects: 90000
Study 33714278 — intervention group
Group type: EXPERIMENTAL
Intervention: CAD screening procedure
Number of subjects: 90000
Study 33714389 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined NIRS and intravascular ultrasound
Number of subjects: 898
Study 33714749 — intervention group
Group type: EXPERIMENTAL
Intervention: Splanchnic nerve block (SNB)
Number of subjects: 25
Study 33715033 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaging modalities (including WBMRI)
Number of subjects: 79
Study 33715160 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-SARS-CoV-2 hyperimmune globulin (hIVIG)
Number of subjects: 0
Study 33715160 — intervention group
Group type: COMPARATOR
Intervention: Convalescent plasma
Number of subjects: 0
Study 33715620 — intervention group
Group type: EXPERIMENTAL
Intervention: eGDR tertile T3 (≤ 4.14 mg/kg/min, highest IR)
Number of subjects: 15773
Study 33715620 — intervention group
Group type: COMPARATOR
Intervention: eGDR tertile T1 (≥ 5.35 mg/kg/min)
Number of subjects: 15773
Study 33715620 — intervention group
Group type: EXPERIMENTAL
Intervention: eGDR in participants with no DKD
Number of subjects: 15773
Study 33715620 — intervention group
Group type: EXPERIMENTAL
Intervention: eGDR in participants with nonalbuminuric DKD
Number of subjects: 15773
Study 33716072 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro fertilization with preimplantation genetic testing for aneuploidy and uterus transplantation followed by frozen embryo transfer.
Number of subjects: 20
Study 33716072 — intervention group
Group type: EXPERIMENTAL
Intervention: Single embryo transfer of a warmed, good-quality, euploid, expanded blastocyst after successful uterus transplantation.
Number of subjects: 20
Study 33716072 — intervention group
Group type: EXPERIMENTAL
Intervention: Time from successful uterus transplantation to first embryo transfer.
Number of subjects: 20
Study 33716072 — intervention group
Group type: EXPERIMENTAL
Intervention: Time from successful uterus transplantation to first clinical pregnancy.
Number of subjects: 20
Study 33716072 — intervention group
Group type: EXPERIMENTAL
Intervention: Time from successful uterus transplantation to first live birth.
Number of subjects: 20
Study 33716072 — intervention group
Group type: EXPERIMENTAL
Intervention: Total live births after successful uterus transplantation and embryo transfer.
Number of subjects: 20
Study 33716134 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported opioid use
Number of subjects: 0
Study 33716134 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time electronic opioid use tracking
Number of subjects: 0
Study 33716499 — intervention group
Group type: EXPERIMENTAL
Intervention: Without anticholinergic
Number of subjects: 2527
Study 33716499 — intervention group
Group type: EXPERIMENTAL
Intervention: With anticholinergic
Number of subjects: 2527
Study 33716499 — intervention group
Group type: EXPERIMENTAL
Intervention: With opioids
Number of subjects: 2527
Study 33716499 — intervention group
Group type: EXPERIMENTAL
Intervention: With dexmedetomidine
Number of subjects: 2527
Study 33716499 — intervention group
Group type: EXPERIMENTAL
Intervention: With IV dexamethasone
Number of subjects: 2527
Study 33716499 — intervention group
Group type: COMPARATOR
Intervention: Various anesthetic agents
Number of subjects: 2527
Study 33716499 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalational agents
Number of subjects: 2527
Study 33716695 — intervention group
Group type: EXPERIMENTAL
Intervention: Random training paradigm
Number of subjects: 0
Study 33716695 — intervention group
Group type: COMPARATOR
Intervention: Block training paradigm
Number of subjects: 0
Study 33716817 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological treatment, specific details not available.
Number of subjects: 0
Study 33716824 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness Training
Number of subjects: 0
Study 33716824 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 33716889 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-immersive Virtual Reality
Number of subjects: 0
Study 33716889 — intervention group
Group type: COMPARATOR
Intervention: Conventional Intervention
Number of subjects: 0
Study 33716934 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally Invasive Ponto Surgery
Number of subjects: 0
Study 33716934 — intervention group
Group type: COMPARATOR
Intervention: Linear Incision Technique With Soft Tissue Preservation
Number of subjects: 0
Study 33716945 — intervention group
Group type: EXPERIMENTAL
Intervention: BETACONNECT
Number of subjects: 0
Study 33716948 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm-Hand Boost Therapy during inpatient stroke rehabilitation
Number of subjects: 0
Study 33716948 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard rehabilitation)
Number of subjects: 0
Study 33717057 — intervention group
Group type: EXPERIMENTAL
Intervention: BCMA-directed Chimeric Antigen Receptor T cells (CART) therapy
Number of subjects: 1
Study 33717057 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone
Number of subjects: 1
Study 33717176 — intervention group
Group type: EXPERIMENTAL
Intervention: Placental malaria vaccine
Number of subjects: 0
Study 33717176 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 33717535 — intervention group
Group type: EXPERIMENTAL
Intervention: Easyhaler (EH)
Number of subjects: 397
Study 33718212 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal immunochemical test (FIT) for CRC screening
Number of subjects: 3165
Study 33718212 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum prostate specific antigen (PSA) and Prostate Health Index (PHI) for male PC screening
Number of subjects: 3165
Study 33718212 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammogram (MMG) for female BC screening
Number of subjects: 3165
Study 33718225 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine
Number of subjects: 0
Study 33718225 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide
Number of subjects: 0
Study 33718228 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic cancer vaccination with peptide CALRLong36, 15 vaccines administered
Number of subjects: 10
Study 33718228 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic cancer vaccination with peptide CALRLong36
Number of subjects: 10
Study 33718234 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel conditioning regimen
Number of subjects: 0
Study 33718294 — intervention group
Group type: EXPERIMENTAL
Intervention: Executive Function Training
Number of subjects: 0
Study 33718294 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 33718302 — intervention group
Group type: EXPERIMENTAL
Intervention: SIRS-defined sepsis
Number of subjects: 0
Study 33718302 — intervention group
Group type: COMPARATOR
Intervention: Age-adapted SOFA-defined sepsis
Number of subjects: 0
Study 33718425 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-resistant group
Number of subjects: 30
Study 33718425 — intervention group
Group type: COMPARATOR
Intervention: Insulin-sensitive group
Number of subjects: 30
Study 33718451 — intervention group
Group type: EXPERIMENTAL
Intervention: High TMAO group
Number of subjects: 179
Study 33718451 — intervention group
Group type: COMPARATOR
Intervention: Low TMAO group
Number of subjects: 179
Study 33719441 — intervention group
Group type: EXPERIMENTAL
Intervention: GLPG1972/S201086, a potent and selective ADAMTS-5 inhibitor, dosage and duration not specified.
Number of subjects: 0
Study 33719441 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified, but implied as untreated or standard treatment.
Number of subjects: 0
Study 33719492 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroanatomic ratios (QRSd indexed for height or left ventricular end-diastole volume)
Number of subjects: 4899
Study 33719721 — intervention group
Group type: EXPERIMENTAL
Intervention: PH FDC SC (subcutaneous injection)
Number of subjects: 500
Study 33719721 — intervention group
Group type: COMPARATOR
Intervention: IV pertuzumab plus trastuzumab
Number of subjects: 500
Study 33719728 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task walking in people with PD MCI
Number of subjects: 93
Study 33719728 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task walking in people with PD non-MCI
Number of subjects: 93
Study 33719728 — intervention group
Group type: COMPARATOR
Intervention: Cognitive status influence on dual-task costs
Number of subjects: 93
Study 33719728 — intervention group
Group type: COMPARATOR
Intervention: Nonmotor experiences of daily living
Number of subjects: 93
Study 33719728 — intervention group
Group type: COMPARATOR
Intervention: TUG-cog (Timed Up and Go cognitive)
Number of subjects: 93
Study 33719728 — intervention group
Group type: COMPARATOR
Intervention: Overall dual-task costs across gait domains
Number of subjects: 93
Study 33720032 — intervention group
Group type: EXPERIMENTAL
Intervention: eVisits for sore throat
Number of subjects: 3847
Study 33720032 — intervention group
Group type: EXPERIMENTAL
Intervention: eVisits for respiratory symptoms
Number of subjects: 3847
Study 33720032 — intervention group
Group type: EXPERIMENTAL
Intervention: eVisits for dysuria
Number of subjects: 3847
Study 33720032 — intervention group
Group type: EXPERIMENTAL
Intervention: eVisits for sore throat (guideline-recommended antibiotics)
Number of subjects: 3847
Study 33720032 — intervention group
Group type: EXPERIMENTAL
Intervention: eVisits for respiratory symptoms (guideline-recommended antibiotics)
Number of subjects: 3847
Study 33720032 — intervention group
Group type: EXPERIMENTAL
Intervention: eVisits for dysuria (guideline-recommended antibiotics)
Number of subjects: 3847
Study 33720067 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonimmunological stromal targeting strategies
Number of subjects: 0
Study 33720067 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor ECM components
Number of subjects: 0
Study 33720067 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor ECM
Number of subjects: 0
Study 33720068 — intervention group
Group type: EXPERIMENTAL
Intervention: NTRK inhibitors
Number of subjects: 0
Study 33720068 — intervention group
Group type: EXPERIMENTAL
Intervention: RET inhibitors
Number of subjects: 0
Study 33720068 — intervention group
Group type: COMPARATOR
Intervention: Multiple kinase inhibitors
Number of subjects: 0
Study 33720071 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathway group (detailed patient education, long-acting nerve block with bupivacaine and dexamethasone, preemptive multimodal analgesia)
Number of subjects: 281
Study 33720071 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathway group
Number of subjects: 281
Study 33720071 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine care)
Number of subjects: 281
Study 33720071 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 281
Study 33720336 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisocabtagene maraleucel (CAR T-cell therapy)
Number of subjects: 268
Study 33720337 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab-based therapies (including R-Dox) with maintenance AZT/VGC or interferon
Number of subjects: 62
Study 33720337 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments administered at investigator discretion
Number of subjects: 62
Study 33720337 — intervention group
Group type: COMPARATOR
Intervention: Concurrent diagnosis of PEL
Number of subjects: 62
Study 33720354 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Number of subjects: 0
Study 33720424 — intervention group
Group type: EXPERIMENTAL
Intervention: pembrolizumab 200 mg every 3 weeks for 3 cycles
Number of subjects: 143
Study 33720513 — intervention group
Group type: EXPERIMENTAL
Intervention: Microduplication in the 10q26.3 region including part of the INPP5A gene
Number of subjects: 3
Study 33720513 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenotyping and genotyping (including CGH-array)
Number of subjects: 3
Study 33720573 — intervention group
Group type: EXPERIMENTAL
Intervention: Anemia
Number of subjects: 1023
Study 33720749 — intervention group
Group type: EXPERIMENTAL
Intervention: Bundled Acupuncture and Yoga Therapy
Number of subjects: 0
Study 33720906 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate OSA
Number of subjects: 869
Study 33720906 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe OSA
Number of subjects: 869
Study 33720906 — intervention group
Group type: EXPERIMENTAL
Intervention: STOP-Bang score of 3-4
Number of subjects: 869
Study 33720906 — intervention group
Group type: EXPERIMENTAL
Intervention: STOP-Bang score of 5-8
Number of subjects: 869
Study 33720906 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing neck circumference
Number of subjects: 869
Study 33720906 — intervention group
Group type: COMPARATOR
Intervention: No OSA
Number of subjects: 869
Study 33721209 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium/Olodaterol
Number of subjects: 42953
Study 33721209 — intervention group
Group type: COMPARATOR
Intervention: LABA/ICS
Number of subjects: 42953
Study 33721213 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 5 mg
Number of subjects: 330
Study 33721213 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 15 mg
Number of subjects: 330